Marshall Wace, LLP I Mab Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.58 - $1.9 $90,097 - $108,345	-57,024 Reduced 80.22%	14,064 $23,000
Q1 2024 May 15, 2024	BUY	$1.54 - $2.37 $109,475 - $168,478	71,088 New	71,088 $132,000
Q2 2022 Aug 15, 2022	BUY	$8.27 - $18.43 $864,033 - $1.93 Million	104,478 New	104,478 $1.18 Million
Q1 2022 May 16, 2022	SELL	$12.54 - $46.93 $160,762 - $601,642	-12,820 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $580,489 - $955,090	12,820 New	12,820 $606,000
Q2 2021 Aug 13, 2021	SELL	$47.86 - $83.95 $2.57 Million - $4.5 Million	-53,596 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$44.38 - $63.97 $4.32 Million - $6.22 Million	-97,289 Reduced 64.48%	53,596 $2.6 Million
Q4 2020 Feb 16, 2021	BUY	$32.94 - $47.15 $2.51 Million - $3.6 Million	76,288 Added 102.27%	150,885 $7.11 Million
Q3 2020 Nov 16, 2020	BUY	$27.46 - $47.03 $2.05 Million - $3.51 Million	74,597 New	74,597 $3.51 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.